Breaking news!

^PrKISQALI^® is now indicated in early breast cancer¹

KISQALI^® (ribociclib tablets) is indicated in combination with an aromatase inhibitor (AI) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II–III early breast cancer at high risk of recurrence. In pre/perimenopausal women, or men, the aromatase inhibitor should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.¹

NATALEE pivotal trial: A randomized, open-label, multicentre, phase III clinical study in pre/post-menopausal women, and men, with HR-positive, HER2-negative, stage II–III early breast cancer irrespective of nodal status, evaluating KISQALI^® in combination with an AI (letrozole or anastrozole) vs. AI alone.

Consult the Product Monograph for conditions of clinical use, contraindications, warnings, precautions, adverse reactions, drug interactions, and dosing information. The Product Monograph is also available by calling 1-800-363-8883.